Results 91 to 100 of about 480,913 (287)

Pharmacotherapy Risks in Rare Genetic Diseases: Cross‐Referencing ACMG Secondary Findings v3.2 List With Clinical Databases

Clinical and Translational Science, Volume 19, Issue 1, January 2026.
ABSTRACT Clinical genomics and pharmacogenomics have largely remained separate fields, though some genetic variants have overlapping disease risk and drug implications. However, the extent of this overlap is not well studied. To explore this gap, we cross‐referenced genes from the American College of Medical Genetics Secondary Findings v3.2 list with ...
Josiah D. Allen, Benjamin Q. Duong, Jordan Brady, Pamela Arn   +3 more
wiley   +1 more source

Identification of Two Rare Variants in Iranian Families With Familial Sudden Cardiac Death

International Journal of Genomics, Volume 2026, Issue 1, 2026.
Cellular action potential is characterized by a particular sequence of depolarizing and repolarizing ion currents regulated by ion channels. Genetic mutations in these channels disrupt the essential movement of ions, such as Na+, Ca++, and K+, across the cell membrane, leading to dangerous arrhythmias and sudden cardiac death (SCD).
Mahsa Tahmasebivand, Sepideh Mehvari, Fatemeh Ghodratpour, Hamidreza Khoram Khorshid, Reza Malekzadeh, Reza Najafipour, Yasser Riazalhosseini, Mark Lathrop, Hossein Najmabadi, Kimia Kahrizi, Neetu Rawal   +10 more
wiley   +1 more source

Sacubitril Does Not Exert Proarrhythmic Effects in Combination with Different Antiarrhythmic Drugs

Pharmaceuticals
Background: Previous studies suggest a direct effect of sacubitril on cardiac electrophysiology and indicate potential arrhythmic interactions between sacubitril and antiarrhythmic drugs.
Christian Ellermann, Carlo Mengel, Julian Wolfes, Felix K. Wegner, Benjamin Rath, Julia Köbe, Lars Eckardt, Gerrit Frommeyer   +7 more
doaj   +1 more source

Hydroxyzine, a First Generation H1-Receptor Antagonist, Inhibits Human Ether-a-go-go–Related Gene (HERG) Current and Causes Syncope in a Patient With the HERG Mutation

Journal of Pharmacological Sciences, 2008
QT prolongation, a risk factor for arrhythmias, can result from genetic variants in one (or more) of the genes governing cardiac repolarization as well as intake of drugs known to affect a cardiac K+ channel encoded by human ether-a-go-go–related gene ...
Tomoko Sakaguchi, Hideki Itoh, Wei-Guang Ding, Keiko Tsuji, Iori Nagaoka, Yuko Oka, Takashi Ashihara, Makoto Ito, Yoshihiro Yumoto, Naoko Zenda, Yukei Higashi, Youichi Takeyama, Hiroshi Matsuura, Minoru Horie   +13 more
doaj   +1 more source

Prolactin Inhibition to Treat Postpartum Arrhythmic Storm

JACC: Case Reports
Postpartum electrical storm due to torsade de pointes is a rare but life-threatening condition. The uniqueness of this case lies in the use of cabergoline to suppress postpartum ventricular arrhythmias in absence of heart disease.
Miriam Compagnone, MD, Alessandro Marinelli, MD, Gianni Dall'Ara, MD, PhD, Matteo Ziacchi, MD, PhD, Simone Grotti, MD, Leonardo Ciurlanti, MD, Fabio Felice Tarantino, MD, Luciano Potena, MD, Mauro Biffi, MD, Marcello Galvani, MD   +9 more
doaj   +1 more source

ECG Round [PDF]

, 1997
published_or_final_versio
Lau, CP, Wan, SH
core  

Screening for QT Prolongation in the Emergency Department: Is There a Better “Rule of Thumb?” [PDF]

, 2020
Introduction: Identification of QT prolongation in the emergency department (ED) is critical for appropriate monitoring, disposition, and treatment of patients at risk for torsades de pointes (TdP).
Friedman, Ari B., Rischall, Megan L., Smith, Stephen W.   +2 more
core  

Successful Management of Refractory Torsades De Pointes Due to Drug-Induced Long QT Syndrome Guided by Point-of-Care Monitoring of Ionized Magnesium [PDF]

, 2021
Chiho Matsuura, Takao Kato, Kaoru Koyama
openalex   +1 more source

Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation – A Systematic Review [PDF]

, 2018
Prolongation of the heart rate‐corrected QT (QTc) interval increases the risk for torsades de pointes (TdP), a potentially fatal arrhythmia. The likelihood of TdP is higher in patients with risk factors, which include female sex, older age, heart failure
Muensterman, Elena Tomaselli, Tisdale, James E.   +1 more
core   +1 more source

Pharmacological cardioversion of atrial fibrillation--a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously [PDF]

, 2011
Aim AZD1305 is a combined ion channel blocker developed for the treatment of atrial fibrillation (AF). The aim of this study was to determine whether AZD1305 was effective in converting AF to sinus rhythm (SR).
Alings, Marco, Berggren, Anders, Bondarov, Patrik, Edvardsson, Nils, Egstrup, Kenneth, Figatowski, Wlodzimierz, Frison, Lars, Gaciong, Zbigniew, Hranai, Marián, Johansson, Susanne, Király, Csaba, Rónaszéki, Aladár, Sereg, Matyas   +12 more
core   +1 more source